Needham Reiterates Buy on Taysha Gene Therapies, Maintains $10 Price Target

Taysha Gene Therapies, Inc. -1.50%

Taysha Gene Therapies, Inc.

TSHA

5.91

-1.50%

Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ: TSHA) with a Buy and maintains $10 price target.